TRPV4 is a Prognostic Biomarker that Correlates with the Immunosuppressive Microenvironment and Chemoresistance of Anti-Cancer Drugs.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed, 23 citations in OpenAlex.

1. Bioinformatic Approach to Identify PotentialInternational journal of molecular sciences · 2025
   Article
2. TRPV4 drives the progression of leiomyosarcoma by promoting ECM1 generation and co-activating the FAK/PI3K/AKT/GSK3β pathway.Cellular oncology (Dordrecht, Netherlands) · 2025
   Article
3. Personalization of Therapy in High-Grade Serous Tubo-Ovarian Cancer-The Possibility or the Necessity?Journal of personalized medicine · 2023
   Review
4. Calcium signals and potential therapy targets in ovarian cancer (Review).International journal of oncology · 2023
   Review
5. "ThermoTRP" Channel Expression in Cancers: Implications for Diagnosis and Prognosis (Practical Approach by a Pathologist).International journal of molecular sciences · 2023
   Review
6. A novel defined risk signature of endoplasmic reticulum stress-related genes for predicting the prognosis and immune infiltration status of ovarian cancer.Journal of Zhejiang University. Science. B · 2023
   Article
7. Transient receptor potential channels as predictive marker and potential indicator of chemoresistance in colon cancer.Oncology research · 2023
   Article
8. Increased Kremen2 predicts worse prognosis in colon cancer.Pathology oncology research : POR · 2023
   Article
9. Anoctamins and Calcium Signalling: An Obstacle to EGFR Targeted Therapy in Glioblastoma?Cancers · 2022
   Review
10. Calcium and calcium-related proteins in endometrial cancer: opportunities for pharmacological intervention.International journal of biological sciences · 2022
    Review
11. Multi-omics analysis identifies distinct subtypes with clinical relevance in lung adenocarcinoma harboringJournal of Cancer · 2022
    Article
12. The Pan-Cancer Landscape of Crosstalk Between TRP Family and Tumour Microenvironment Relevant to Prognosis and Immunotherapy Response.Frontiers in immunology · 2022
    Article
13. TRPs in Ovarian Serous Cystadenocarcinoma: The Expression Patterns, Prognostic Roles, and Potential Therapeutic Targets.Frontiers in molecular biosciences · 2022
    Article
14. Development and validation of a TRP-related gene signature for overall survival prediction in lung adenocarcinoma.Frontiers in genetics · 2022
    Article
15. Transient receptor potential vanilloid type 4 (TRPV4) promotes tumorigenesisFrontiers in molecular biosciences · 2022
    Article
16. Deciphering the Pyroptosis-Related Prognostic Signature and Immune Cell Infiltration Characteristics of Colon Cancer.Frontiers in genetics · 2021
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

8 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as